SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS (PSA) THROUGH 3 YEARS: EFFICACY AND SAFETY RESULTS FROM A PHASE 3 TRIAL - Hall, S.; Mease, P.; Kavanaugh, A.; Reimold, A.; Tahir, H.; Rech, Jürgen; Geusens, P.; Pascale, P.; Delicha, E.; Pricop, L.; Mpofu, S. (2017)
EVALuna2:35048